Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
Serum cuts Covishield dose price as India widens booster programme
Serum Institute of India has cut the price of its Covishield COVID-19 vaccine as the country plans to offer booster doses to all adults from Sunday.
Published : 9 April 2022, 01:50 PM
Updated : 9 April 2022, 01:50 PM
The price will drop to 225 rupees ($2.96) a dose from 600 rupees for private hospitals, the chief executive of SII said in a Tweet on Saturday.
"After discussion with the central government, SII has decided to revise the price of Covishield vaccine for private hospitals," Adar Poonawalla said in a Tweet.
SII, the world's biggest vaccine maker, produces AstraZeneca's COVID-19 vaccine under the brand name Covishield.
Of the 1.85 billion vaccine doses India has supplied to its population of 1.35 billion, 82 percent have been Covishield.
Those over 18 who received a second dose nine months ago will be eligible for the additional "precaution" dose, the health ministry said on Friday, using the government's term for boosters.
The booster programme, which started in January, is limited to frontline workers and the elderly and has so far administered 24 million doses.
When the programme is extended on Sunday, those outside the two priority categories will have to pay for the shots at privately run facilities, with no mixing and matching of vaccines allowed.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
